SPECT/CT Dosimetry of Bronchial Artery 99mTc Macroaggregated Albumin Injection in Pulmonary Malignancies: Feasibility Evaluation of Bronchial Artery 90Y Radioembolization.

Abstract

Background External beam radiation therapy for primary and secondary pulmonary malignancies has limited utility for treating ultracentral tumors (ie, adjacent to the proximal bronchial tree or heart) or multiple metastases due to either radiation to central organs at risk (OARs) or extensive lung tissue exposure. Bronchial artery yttrium 90 (⁹⁰Y) radioembolization may be a therapeutic option for these patients. Purpose To evaluate the feasibility of bronchial artery ⁹⁰Y radioembolization using technetium 99m (^99mTc) macroaggregated albumin (MAA) injection as a surrogate for ⁹⁰Y microspheres and to use SPECT/CT dosimetry to assess ^99mTc-MAA distribution and calculated anticipated ⁹⁰Y doses to tumors and OARs. Materials and Methods In this prospective clinical trial, study participants with either primary lung cancer or pulmonary metastases were enrolled between August 2020 and October 2023 from a single academic medical center. All participants underwent bronchial artery embolization for malignancy-induced hemoptysis prophylaxis. ^99mTc-MAA was injected via bronchial arteries, followed by bland embolization. SPECT/CT imaging and Monte Carlo simulations were used to evaluate ^99mTc-MAA distribution and predict ⁹⁰Y doses. Predicted ⁹⁰Y doses to tumors and OARs are reported as means ± SDs. Results Eight participants (mean age, 63.0 years ± 13.58; six [75%] male participants) were included. All had ultracentral tumors, and four had four or more tumors. SPECT/CT revealed a concentrated ^99mTc-MAA accumulation in tumors, with a mean tumor-to-normal tissue ratio of 22.71 ± 20.17. Simulations indicated that a ⁹⁰Y biologically effective dose (α/β ratio of 10 Gy) of 175.7-3173.6 Gy (mean, 778.8 Gy ± 981.9) could be delivered to all tumors while remaining under OAR toxicity thresholds. Conclusion SPECT/CT dosimetric analysis of ^99mTc-MAA injected via the bronchial artery for pulmonary malignancy suggests that bronchial artery ⁹⁰Y radioembolization is feasible and could be an alternative treatment for patients unable to receive external beam radiation therapy. ClinicalTrials.gov Identifier: NCT04105283 © RSNA, 2025 Supplemental material is available for this article.